Production (Stage)
Celldex Therapeutics, Inc.
CLDX
$20.34
-$0.92-4.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 695.00K | 1.18M | 3.19M | 2.50M | 156.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 695.00K | 1.18M | 3.19M | 2.50M | 156.00K |
| Cost of Revenue | 52.61M | 46.94M | 45.26M | 39.69M | 31.66M |
| Gross Profit | -51.92M | -45.76M | -42.07M | -37.19M | -31.51M |
| SG&A Expenses | 10.82M | 10.26M | 10.05M | 9.13M | 9.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 63.43M | 57.20M | 55.32M | 48.82M | 40.76M |
| Operating Income | -62.74M | -56.03M | -52.13M | -46.32M | -40.61M |
| Income Before Tax | -53.80M | -47.09M | -42.12M | -35.84M | -32.81M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -53.80M | -47.09M | -42.12M | -35.84M | -32.81M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -53.80M | -47.09M | -42.12M | -35.84M | -32.81M |
| EBIT | -62.74M | -56.03M | -52.13M | -46.32M | -40.61M |
| EBITDA | -61.87M | -55.21M | -51.34M | -45.52M | -39.83M |
| EPS Basic | -0.81 | -0.71 | -0.64 | -0.54 | -0.56 |
| Normalized Basic EPS | -0.51 | -0.44 | -0.40 | -0.34 | -0.35 |
| EPS Diluted | -0.81 | -0.71 | -0.64 | -0.54 | -0.56 |
| Normalized Diluted EPS | -0.51 | -0.44 | -0.40 | -0.34 | -0.35 |
| Average Basic Shares Outstanding | 66.38M | 66.35M | 66.29M | 66.02M | 58.87M |
| Average Diluted Shares Outstanding | 66.38M | 66.35M | 66.29M | 66.02M | 58.87M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |